

INVITATION TO PRESENTATION OF CINCLUS PHARMA'S FOURTH QUARTER REPORT 2024

Cinclus Pharma's fourth quarter report for October – December 2024 will be published on Thursday, February 20, 2024, at 08:00 am CET. The company will host a live presentation the same day at 10:00 am CET.

The report is presented by CEO Christer Ahlberg and CFO Maria Engström. The presentation includes a Q&A session.

To participate, please follow this link: <https://financialhearings.com/event/51346>

The report, the presentation and a recorded version of the presentation will also be available on the company's website: <https://cincluspharma.com/investors/financial-reports/>

For additional information, please contact:

Christer Ahlberg, CEO
Phone: +46 70 675 33 30
e-mail: christer.ahlberg@cincluspharma.com

Charlotte Stjerngren, IR
Phone: +46 70 876 87 87
e-mail: charlotte.stjerngren@cincluspharma.com

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a clinical late stage pharma company developing a small molecule for the treatment of gastric acid-related diseases and disorders of the upper gastrointestinal tract. Its drug candidate linaprazan glurate represents a novel class of drugs, Potassium-Competitive Acid Blockers (P#CAB), and provides a fast-acting control of intragastric pH by a different mechanism of action than proton pump inhibitors (PPIs), with unique capacity to deliver acid control, pH>4, around the clock. For more information, please visit www.cincluspharma.com.

Attachments

[Invitation to presentation of Cinclus Pharma's fourth quarter report 2024](#)